|Chemical and physical data|
|Molar mass||487.51 g·mol−1|
|3D model (JSmol)|
Sarecycline (trade name Seysara; development code WC-3035) is a tetracycline-derived antibiotic. In the United States, it was approved by the FDA in October 2018 for the treatment of moderate to severe acne vulgaris.
Paratek Pharmaceuticals, Inc. licensed the US rights to sarecycline for the treatment of acne in the United States to Actavis, a subsidiary of Allergan, while retaining rights in the rest of the world.
Allergan initiated a Phase 3 study in December 2014 evaluating the efficacy and safety of sarecycline tablets 1.5 mg/kg per day taken orally for 12 weeks versus placebo in the treatment of acne vulgaris. Two phase 3 randomized, multi-center, double-blind, placebo-controlled studies evaluating the efficacy and safety of sarecycline in moderate to severe acne reported positive results on 27 March 2017.
- "FDA Approves Sarecycline for Moderate to Severe Acne". MedScape. October 2, 2018.
- "Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne - Full Text View - ClinicalTrials.gov".
- "Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne". www.globenewswire.com. Retrieved 16 May 2017.
- Sarecycline - Almirall S.A./Paratek Pharmaceuticals, Adis Insight